DiamiR and AlzLabs Team Up on Blood-Based Alzheimer's Biomarkers
Two diagnostics firms will combine protein and microRNA data to advance blood-based detection of Alzheimer's disease.
A new collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics could push Alzheimer's diagnosis closer to a simple blood draw. The two companies, backed by Nasdaq-listed Aptorum Group, announced plans to jointly generate biomarker data — specifically protein and microRNA signatures — drawn from blood samples of patients with the disease. The partnership was announced Monday from New York, New Haven, and Princeton.
Blood-based diagnostics for Alzheimer's represent one of the most competitive frontiers in neurology. Traditional diagnosis has long depended on costly PET brain scans or invasive cerebrospinal fluid tests, making affordable, accessible alternatives a significant clinical and commercial prize. By pairing microRNA profiling — DiamiR's core competency — with protein biomarker analysis through AlzLabs, the collaboration aims to build a more complete biological picture of how Alzheimer's manifests in the bloodstream.
Read more A Major Steakhouse Chain Shuts 24 Locations Amid Casual Dining Pressure →
For Aptorum Group, which describes itself as a clinical-stage biopharmaceutical company focused on unmet medical needs, the deal extends its diagnostics portfolio beyond traditional drug development. DiamiR's broader platform targets brain health and other disease areas, meaning data generated through the AlzLabs partnership could eventually inform diagnostic tools well beyond Alzheimer's alone. The strategic logic is clear: richer, multi-modal biomarker datasets tend to produce more reliable and clinically actionable tests.
The announcement offers no timeline for data readouts or commercialization milestones, and the financial terms of the arrangement were not disclosed. Still, the move signals growing industry conviction that a scalable, blood-based Alzheimer's test is within reach — a development that would carry enormous implications for early intervention and healthcare cost containment. Continue reading at GlobalNewswire.
